FDA Continues Review of Cancer Risk Associated with TNF blockers, Azathioprine, and/or Mercaptopurine - MPR
Links shared publicly online about this topic.
- 365total visits
FDA Continues Review of Cancer Risk Associated with TNF blockers, Azathioprine, and/or Mercaptopurine - MPR
empr.com —
The FDA continues to receive reports of hepatosplenic T-Cell lymphoma (HSTCL) in adolescents and young adults treated for Crohn--™s disease and ulcerative colitis with tumor necrosis factor (TNF) blockers, as well as azathioprine, and/or mercaptopurine.
View full resource at empr.com
Tags: Crohn's Disease Medication, Cancer, Lymphoma, Non-Hodgkin Lymphoma, FDA, Imuran, News
Most Recently Shared on April 14, 2011 at 6:50 pm By:
MPR News: FDA Continues Review of Cancer Risk Associated with TNF blockers, Azathioprine, and/or Mercaptopurine:... http://bit.ly/gT2YaE
Advertisement
